Renaissance Technologies LLC Purchases New Position in Microbot Medical Inc. (NASDAQ:MBOT)

Renaissance Technologies LLC acquired a new position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned approximately 0.52% of Microbot Medical as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its holdings in Microbot Medical by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after buying an additional 10,442 shares in the last quarter. Institutional investors own 16.30% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a report on Thursday, April 10th.

Microbot Medical Price Performance

NASDAQ:MBOT traded down $0.09 during midday trading on Tuesday, reaching $2.46. The stock had a trading volume of 703,813 shares, compared to its average volume of 2,200,973. The stock has a market capitalization of $85.47 million, a P/E ratio of -3.07 and a beta of 1.15. Microbot Medical Inc. has a 1-year low of $0.82 and a 1-year high of $3.38. The firm's fifty day simple moving average is $1.94 and its 200-day simple moving average is $1.60.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, equities research analysts anticipate that Microbot Medical Inc. will post -0.71 earnings per share for the current fiscal year.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.